RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340

Benzinga · 1d ago
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $262 to $340.